Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Infection ; 51(2): 475-482, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36201152

ABSTRACT

PURPOSE: This case series describes real-world utilization of cefiderocol and associated clinical outcomes in the setting of carbapenem-resistant Gram-negative bacterial infections. METHODS: Adult hospitalized patients administered at least 5 days of cefiderocol as definitive treatment from October 1, 2020 to September 16, 2021 were included in this retrospective cohort analysis. The primary outcome was clinical success defined as a composite of 30 day survival, resolution of infection, and absence of 30 day recurrence of the same organism. RESULTS: Among 24 patients, pneumonia (19, 79%) was the most common source of infection with Acinetobacter baumannii (14, 58%) and P. aeruginosa (10, 42%) as the predominant organisms isolated. Cefiderocol monotherapy was used as definitive treatment in 16 (67%) patients. Eleven patients (46%) met clinical success. Thirty-day mortality occurred in ten (42%) patients while seven (29%) patients had recurrence of infection. Thirteen out of 21 total isolates (62%) tested for susceptibility were deemed susceptible. Of the 16 patients with available susceptibility, 9 (56%) had an infection where all isolated organisms were susceptible to cefiderocol. CONCLUSIONS: Our results provide additional insight into the in vivo activity of cefiderocol. Cefiderocol remains a salvage option for carbapenem-resistant Gram-negative organisms.


Subject(s)
Anti-Bacterial Agents , Carbapenems , Adult , Humans , Carbapenems/pharmacology , Carbapenems/therapeutic use , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Salvage Therapy , Retrospective Studies , Gram-Negative Bacteria , Drug Resistance, Multiple, Bacterial , Cephalosporins/pharmacology , Cephalosporins/therapeutic use , Microbial Sensitivity Tests , Cefiderocol
2.
Science ; 356(6335): 307-311, 2017 04 21.
Article in English | MEDLINE | ID: mdl-28428423

ABSTRACT

The African naked mole-rat's (Heterocephalus glaber) social and subterranean lifestyle generates a hypoxic niche. Under experimental conditions, naked mole-rats tolerate hours of extreme hypoxia and survive 18 minutes of total oxygen deprivation (anoxia) without apparent injury. During anoxia, the naked mole-rat switches to anaerobic metabolism fueled by fructose, which is actively accumulated and metabolized to lactate in the brain. Global expression of the GLUT5 fructose transporter and high levels of ketohexokinase were identified as molecular signatures of fructose metabolism. Fructose-driven glycolytic respiration in naked mole-rat tissues avoids feedback inhibition of glycolysis via phosphofructokinase, supporting viability. The metabolic rewiring of glycolysis can circumvent the normally lethal effects of oxygen deprivation, a mechanism that could be harnessed to minimize hypoxic damage in human disease.


Subject(s)
Adaptation, Physiological , Anaerobiosis , Brain/physiology , Fructose/metabolism , Glycolysis , Mole Rats/metabolism , Oxygen/metabolism , Animals , Brain/metabolism , Fructokinases/metabolism , Glucose Transporter Type 5/metabolism , Lactic Acid/metabolism , Mice , Myocardium/metabolism , Sucrose/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...